

Review of: "[Perspective] Exploring the Synergistic Approach of Dual GLP-1 Agonist with Degludec Basal Insulin for Type 1 Diabetes Treatment for Albumin-InsulinProducing Cells Expression"

Silvia Pellitero¹

¹ Generalitat de Catalunya

Potential competing interests: No potential competing interests to declare.

The article mentioned on the use of GLP-1 analogues in the onset of type 1 diabetes observes a period of time without using insulin that could correspond to the honeymoon phase, which these patients have in the first or even second year. (which is very common in clinical practice). Everything said about the improvement in the half-life of beta cells must be demonstrated in a group of experimental animals with a control group. I agree with the need for a prospective study in humans to get closer to this working hypothesis. although the use of GLP-1 analogues in type 1 diabetes should be taken into account at the beginning of the disease (when there is residual beta cell) or throughout the disease. Control group would be type 1 diabetes-naïve patients without GLP-1 analogues. This future study would be interesting.